Literature DB >> 16438077

Expression of bcl-2 in papillary thyroid cancers and its prognostic value.

M Aksoy1, Y Giles, Y Kapran, T Terzioglu, S Tezelman.   

Abstract

PURPOSE: Papillary thyroid cancer has a good prognosis. This favourable prognosis may be attributed to the apoptotic tendency of the cancer cells. This study aims to evaluate the expression of bcl-2, which is an antidote of apoptosis, and aims to evaluate the value of bcl-2 as a prognostic marker in papillary thyroid cancer. MATERIAL-
METHODS: Bcl-2 expression in the archival materials of 31 patients with papillary thyroid cancer was examined with immunohistochemical methods using bcl-2 and p-53 stains. The results were compared with 31 normal thyroid tissue specimens, which consisted of the contralateral lobes of these patients. The results were then analyzed in accordance with the clinical features of the patients.
RESULTS: Thirty (96.7%) patients of the control group were positive for bcl-2 whilst one (3.3%) was negative. The staining for bcl-2 was positive in 12 (%75) patients with microcarcinomas (p < 0.05) and 13 (86.6%) with papillary cancers (p > 0.05). Two cases of the papillary cancer group were admitted to the hospital with local recurrence (6.4%) and both were positive for bcl-2 (p > 0.05). All cases (4/31), whose MACIS scores were higher than 7 were positive for bcl-2. Twenty-one of 27 cases whose MACIS scores were lower than 7 (77.7%) were positive for bcl-2 (p > 0.05). All tumours of this series were negative for p-53 immunstaining.
CONCLUSION: The rate of bcl-2 expression in microcarcinomas of papillary thyroid cancer decreases when compared to normal thyroid tissue. This may be an early sign of oncogenesis, and a reason for the favourable prognosis in microcarcinomas. However, bcl-2 cannot be used as a prognostic marker.

Entities:  

Mesh:

Year:  2005        PMID: 16438077     DOI: 10.1080/00015458.2005.11679794

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  7 in total

1.  Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.

Authors:  A Z Balta; A I Filiz; Y Kurt; I Sucullu; E Yucel; M L Akin
Journal:  Med Oncol       Date:  2011-05-06       Impact factor: 3.064

2.  Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.

Authors:  Sonja A Selemetjev; Svetlana B Savin; Ivan R Paunovic; Svetislav B Tatic; Dubravka Cvejic
Journal:  Wien Klin Wochenschr       Date:  2014-12-04       Impact factor: 1.704

3.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

Authors:  Krzysztof Fujarewicz; Michal Jarzab; Markus Eszlinger; Knut Krohn; Ralf Paschke; Małgorzata Oczko-Wojciechowska; Małgorzata Wiench; Aleksandra Kukulska; Barbara Jarzab; Andrzej Swierniak
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

4.  Identification of thyroid carcinoma related genes with mRMR and shortest path approaches.

Authors:  Yaping Xu; Yue Deng; Zhenhua Ji; Haibin Liu; Yueyang Liu; Hu Peng; Jian Wu; Jingping Fan
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

5.  An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated Analysis.

Authors:  Monika Lamba Saini; Caroline Bouzin; Birgit Weynand; Etienne Marbaix
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 6.  Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours.

Authors:  D Cvejic; S Selemetjev; S Savin; I Paunovic; S Tatic
Journal:  Eur J Histochem       Date:  2009-06-29       Impact factor: 3.188

7.  In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma.

Authors:  Asma Almansoori; Poorna Manasa Bhamidimarri; Riyad Bendardaf; Rifat Hamoudi
Journal:  Int J Gen Med       Date:  2022-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.